Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 9, 2000, Pages 2356-2360

  Santangelo, R ^a   Paderu, P ^a   Delmas, G ^a   Chen, Z W ^a   Mannino, R ^a   Zarif, L ^a   Perlin, D S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B DERIVATIVE; AMPHOTERICIN B LIPID COMPLEX; COCHLEATE AMPHOTERICIN B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ANTIFUNGAL ACTIVITY; ARTICLE; BODY BURDEN; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDIASIS; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; KIDNEY; LUNG; MICE; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 0033844882     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.9.2356-2360.2000     Document Type: Article

References (46)

1. AmBisome targeting to fungal infections
2. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B
3. Treatment of routine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)
4. Predictors of adverse outcome in cancer patients with candidemia
5. Treatment of opportunistic fungal infections
6. Liposomes: Realizing their promise
7. Secular trends in the epidemiology of nosocomial fungal infections in the United States 1980-1990. National Nosocomial Infections Surveillance System
8. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B
9. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: Molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses
10. Amphotericin B: Current understanding of mechanisms of action
11. Absorption of orally administered amphotericin B lozenges
12. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate
13. Double-blind cross-over study of phosphatidylserine vs placebo in patients with early dementia of the Alzheimer type
14. Candidemia in a tertiary care hospital: Epidemiology, risk factors, and predictors of mortality
15. Amphotericin B: A commentary on its role as an antifungal agent and as a comparative agent in clinical trials
16. Amphotericin B: 30 years of clinical experience
17. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation
18. Lipid formulations of amphotericin B: Clinical perspectives for the management of invasive fungal infections in children with cancer
19. Development of liposomal amphotericin B formulation
20. Liposomal amphotericin B, AmBisome
21. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations
22. Lipid formulations of amphotericin B: Recent progress and future directions
23. Antibiotic-related nephrotoxicity
24. Prospective multicenter surveillance study of funguria in hospitalized patients
25. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
26. Antigen cochleate formulations for oral and systemic vaccination in new generation vaccines
27. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
28. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients
29. Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles
30. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group
31. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
32. A comparative review of conventional and lipid formulations of amphotericin B
33. Amphotericin B nephrotoxicity
34. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties
35. Safety of high-dose amphotericin B lipid complex
36. Multicenter clinical trial of brain phosphatidylserine in elderly patients with intellectual deterioration
37. Invasive fungal infections in children: Recent advances in diagnosis and treatment
38. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
39. Safety, tolerance, and pharmaco-kinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
40. Amphotericin B: An introduction
41. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
42. Nosocomial Candida. Epidemiology, transmission, and prevention
43. Cochleates: Lipid-based vehicles for gene delivery - Concept, achievements and future development
44. Antifungal activity of amphotericin B cochleates against Candida albicans infection in a mouse model
45. Oral and systemic delivery of AmB mediated by cochleates